Adjuvant gefitinib compared to chemotherapy after lung cancer resection did not improve survival
1. The median disease-free survival for gefitinib group and cisplatin/vinorelbine group was 35.9 and 25.1 months, respectively. 2. Patients receiving...
Oncology
Reports of high-impact oncology studies by medical professionals
Risk of adverse outcomes from COVID-19 is higher for patients with cancer
1. COVID-19 patients with cancer had increased rates of hospitalization, ICU stay, and mortality than patients without cancer. 2. Patients...
Phototherapy not associated with increased risk of childhood cancer
1. In a large cohort, phototherapy for neonatal hyperbilirubinemia is not associated with any childhood cancer. Evidence Rating Level: 2...
Maintenance olaparib, compared with placebo, reduces the risk of disease progression in patients with advanced BRCA mutation ovarian cancer
1. Median progression-free survival was 56.0 months in the olaparib group and was 13.8 months in the placebo group. 2....
Cabozantinib is associated with an intracranial response in the treatment of brain metastases from renal cell carcinoma
1. Intracranial response rate of 55% was reported in patients receiving cabozantinib with progressing brain metastases with no concomitant brain-directed...
Nivolumab is a potential treatment option for patients with relapsing malignant mesothelioma
1. Overall survival was 6.9 months in the placebo group and 10.2 months in the nivolumab group. 2. Progression free...
Adjuvant atezolizumab shows benefit in patients with stage II-IIIA non-small-cell lung cancer
1. Atezolizumab showed a benefit for disease-free survival in patients with stage II-IIIA NSCLC compared to best supportive treatment. 2....
Incidence of keratinocyte carcinoma disproportionately rising for young females over past two decades r
Incidence and mortality rates of keratinocyte carcinoma from 1998-2017: A population-based study of sex differences in Ontario, Canada 1. The...
Mobocertinib is a tolerable and possible treatment option for patients with EGFR exon 20 insertion mutated advanced non-small-cell lung cancer
1. Overall response rate was 28% and 35% in the platinum pretreated cohort (PPP) and 25% and 32% in the...
Camrelizumab with apatinib is a well-tolerated treatment for chemo-refractory or relapsed gestational trophoblastic neoplasia
1. Camrelizumab and apatinib treatment provided a 55% objective response rate 2. A complete response was observed in 50% of...
Popular Reports
-
Peripherally inserted central catheters are associated with twice as many complications than midline catheters when used short-term
-
Capecitabine + oxaliplatin chemoradiotherapy does not increase survival, but increases toxicity, compared to capecitabine alone in the postoperative treatment of rectal cancer
-
Ultrasound features associated with shoulder complaints
-
Automated pupillometry may be helpful in opioid agonist therapy dosing for opioid use disorder
-
The Child-Pugh score: Prognosis in chronic liver disease and cirrhosis [Classics Series]
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.